Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Information

The following table contains quarterly financial information for 2017 and 2016. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

	2017
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter			Total
	(in thousands, except per share data)
Total revenue	$	425		$	—		$	—		$	—		$	425
Total operating expenses	6,587			7,350			9,150			$	6,593		29,680
Loss from operations	(6,162		)	(7,350		)	(9,150		)	$	(6,593	)	(29,255		)
Net loss	(6,061		)	(7,316		)	(9,105		)	$	(6,547	)	$	(29,029	)
Net loss per share—basic and diluted	$	(0.25	)	$	(0.30	)	$	(0.37	)	$	(0.22	)	$	(1.11	)

	2016
	First Quarter			Second Quarter			Third Quarter *		Fourth Quarter			Total
	(in thousands, except per share data)
Total revenue	$	229		$	277		$	28,650	$	825		$	29,981
Total operating expenses	6,779			6,769			9,120		4,447			27,115
Income (loss) from operations	(6,550		)	(6,492		)	19,530		(3,622		)	2,866
Net income (loss)	(7,574		)	(6,491		)	19,487		(3,531		)	1,891
Net income (loss) per share—basic	$	(0.39	)	$	(0.33	)	$	0.95	$	(0.15	)	$	0.09
Net income (loss) per share—diluted	$	(0.39	)	$	(0.33	)	$	0.91	$	(0.15	)	$	0.09

* In the third quarter of 2016, the Company recognized revenue of $29.0 million in connection with the License Agreement with Roche. In addition, the Company incurred $2.5 million of transaction costs associated with the Acquisition of Viventia.